LEFLUNOMIDE GENERICHEALTH (Southern Cross Pharma Pty Ltd)
Product name
LEFLUNOMIDE GENERICHEALTH
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
44 working days (255)
Active ingredients
leflunomide
Registration type
EOI
Indication
Generic medicine
LEFLUNOMIDE GENERICHEALTH is now also indicated for the treatment of active psoriatic arthritis. Leflunomide Generichealth is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. The combined use of Leflunomide Generichealth with other Disease Modifying Anti-Rheumatic Drugs (DMARDs) has not been adequately studied.